Literature DB >> 12215008

Regulation of gene expression by WT1 in development and tumorigenesis.

Leif W Ellisen1.   

Abstract

WT1 encodes a zinc finger transcription factor implicated in normal development and tumorigenesis. Germline mutation or deletion of WT1 results in a spectrum of abnormal kidney development, male-to-female intersex disorders, and predisposition to pediatric nephroblastoma, Wilms tumor. Initially thought to encode a transcriptional repressor, WT1-dependent functions are now more clearly linked to its property as a transcriptional activator of genes involved in renal development and sex determination. WT1 is expressed in 4 isoforms as a result of 2 alternative messenger RNA splicing events, the more significant of which encodes the 3 amino acids lysine, threonine, and serine (KTS) between zinc fingers 3 and 4. Although WT1 isoforms lacking KTS act as sequence-specific DNA binding factors, a large body of evidence now implicates the KTS-containing isoforms in RNA processing. In keeping with distinct biochemical mechanisms for these isoforms, genetic data from humans and mice point to separate but partially overlapping roles for WT1 (+KTS) and (-KTS) during genitourinary development. Recently, a hematopoietic model system has been used to study functional properties of WT1 in vitro. WT1 expression in primary hematopoietic cells leads to stage-specific effects that may be relevant to WT1-mediated tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215008     DOI: 10.1007/BF02982572

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  53 in total

1.  Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.

Authors:  S M Hewitt; G F Saunders
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

2.  Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression.

Authors:  M W Nachtigal; Y Hirokawa; D L Enyeart-VanHouten; J N Flanagan; G D Hammer; H A Ingraham
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

3.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

4.  Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins.

Authors:  G Holmes; S Boterashvili; M English; B Wainwright; J Licht; M Little
Journal:  Biochem Biophys Res Commun       Date:  1997-04-28       Impact factor: 3.575

5.  Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.

Authors:  N Bardeesy; J Pelletier
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

6.  Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site.

Authors:  H Werner; F J Rauscher; V P Sukhatme; I A Drummond; C T Roberts; D LeRoith
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

7.  Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome.

Authors:  P N Baird; A Santos; N Groves; L Jadresic; J K Cowell
Journal:  Hum Mol Genet       Date:  1992-08       Impact factor: 6.150

8.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

9.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing.

Authors:  S H Larsson; J P Charlieu; K Miyagawa; D Engelkamp; M Rassoulzadegan; A Ross; F Cuzin; V van Heyningen; N D Hastie
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

10.  The evolution of WT1 sequence and expression pattern in the vertebrates.

Authors:  J Kent; A M Coriat; P T Sharpe; N D Hastie; V van Heyningen
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

View more
  7 in total

1.  Global analysis of HuR-regulated gene expression in colon cancer systems of reducing complexity.

Authors:  Isabel López de Silanes; Jinshui Fan; Craig J Galbán; Richard G Spencer; Kevin G Becker; Myriam Gorospe
Journal:  Gene Expr       Date:  2004

Review 2.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

3.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

Review 4.  Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF.

Authors:  Jelena Veljkovic; Ulla Hansen
Journal:  Gene       Date:  2004-12-08       Impact factor: 3.688

5.  Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms's tumours.

Authors:  J Alami; B R Williams; H Yeger
Journal:  Mol Pathol       Date:  2003-08

6.  Wilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line.

Authors:  Rosalba Parenti; Venera Cardile; Adriana Carol Eleonora Graziano; Carmela Parenti; Assunta Venuti; Maria Paola Bertuccio; Debora Lo Furno; Gaetano Magro
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

7.  Expression profile of Wilms Tumor 1 (WT1) isoforms in undifferentiated and all-trans retinoic acid differentiated neuroblastoma cells.

Authors:  Grazia Maugeri; Agata Grazia D'Amico; Daniela Maria Rasà; Rita Reitano; Salvatore Saccone; Concetta Federico; Rosalba Parenti; Gaetano Magro; Velia D'Agata
Journal:  Genes Cancer       Date:  2016-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.